Thomas Edwards Biography and Net Worth

Director of ChemoCentryx

Thomas Edwards has served on our board of directors since July 2015. Prior to his retirement from Latham & Watkins in 2014, Mr. Edwards supported dozens of biopharmaceutical companies in their general legal efforts, capital financings, acquisitions, partnerships and numerous other strategic business and legal initiatives. Mr. Edwards regularly represented companies and investment banking firms in public offerings, private placements, venture capital financings and corporate partnering arrangements. Mr. Edwards is a member of the American, California and San Diego Bar Associations. Mr. Edwards earned his bachelor's degree from Harvard College and his law degree from Harvard Law School.

What is Thomas A. Edwards' net worth?: The estimated net worth of Thomas A. Edwards is at least $6.26 million as of March 2nd, 2021. Mr. Edwards owns 120,457 shares of ChemoCentryx stock worth more than $6,262,559 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Edwards may own. Learn More about Thomas A. Edwards' net worth.
How do I contact Thomas A. Edwards?: The corporate mailing address for Mr. Edwards and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at [email protected]. Learn More on Thomas A. Edwards' contact information.
Has Thomas A. Edwards been buying or selling shares of ChemoCentryx?: Thomas A. Edwards has not been actively trading shares of ChemoCentryx within the last three months. Most recently, Thomas A. Edwards sold 1,100 shares of the business's stock in a transaction on Tuesday, March 2nd. The shares were sold at an average price of $70.06, for a transaction totalling $77,066.00. Following the completion of the sale, the director now directly owns 120,457 shares of the company's stock, valued at $8,439,217.42. Learn More on Thomas A. Edwards' trading history.
Who are ChemoCentryx's active insiders?: ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Thomas A. Edwards Insider Trading History at ChemoCentryx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/2/2021	Sell	1,100	$70.06	$77,066.00	120,457
2/9/2021	Sell	400	$70.04	$28,016.00	120,957
2/2/2021	Sell	20,000	$60.94	$1,218,800.00	129,340
12/28/2020	Sell	10,782	$61.50	$663,093.00	152,139
12/24/2020	Sell	14,218	$61.18	$869,857.24	152,139
5/17/2016	Buy	50,000	$4.05	$202,500.00	91,977
5/16/2016	Buy	25,000	$4.05	$101,250.00	41,977

Thomas A. Edwards Buying and Selling Activity at ChemoCentryx

ChemoCentryx Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Today's Range

Now: $51.99

$51.99

50 Day Range

MA: $51.95

$51.66

$51.99

2 Week Range

Now: $51.99

$14.95

$52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

Claim your free seat by clicking here now.